Myrobalan Therapeutics is focused on developing innovative small molecule therapies aimed at addressing critical issues in central nervous system (CNS) diseases, particularly those related to neuroinflammation and demyelination. Their research targets key mechanisms involved in conditions such as multiple sclerosis, Alzheimer's disease, ALS, and Parkinson's disease. The company is advancing several promising candidates, including a CSF1R inhibitor that aims to eliminate dysfunctional microglia, thereby reducing neuroinflammation and promoting remyelination. Additionally, their GPR17 antagonist is designed to facilitate the differentiation and maturation of oligodendrocyte precursor cells, which is essential for repairing myelin damage. Myrobalan's approach emphasizes the importance of high CNS distribution and a favorable safety profile, ensuring that their therapies can effectively reach and treat the affected areas of the brain.

The company employs a biomarker-guided precision neurology strategy to tailor their therapies to specific patient populations, enhancing the potential for clinical efficacy. Their pipeline includes a TYK2 inhibitor, which is notable for its ability to penetrate the blood-brain barrier and address sustained neuroinflammation, a common challenge in CNS disorders. Myrobalan's commitment to pioneering first-in-class and best-in-class therapies is supported by a multidisciplinary research and development team, drawing on groundbreaking research from esteemed institutions like Harvard and MIT. This foundation positions Myrobalan Therapeutics at the forefront of CNS drug development, with the goal of delivering transformative treatments for patients with significant unmet medical needs.

United States

Developing therapeutics to address the unmet need and societal burdens posed by neurodegenerative, demyelinating and neuropsychiatric disorders.

Myrobalan Therapeutics

Company Details